Posted by Michael Wonder on 13 Oct 2024
US FDA approves Dong-A ST’s Imuldosa (ustekinumab-srlf), a biosimilar to Stelara
11 October 2024 - Dong-A ST announced on October 11 2024 that Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar referencing Stelara, has won US FDA approval.
As its second FDA approved biosimilar after Sivextro (tedizolid phosphate) in 2014, the company has once again demonstrated its R&D competence.
